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Abstract: Background: Residents of a large area of north-eastern Italy were exposed for decades to high
concentrations of perfluoroalkyl and polyfluoroalkyl substances (PFAS) via drinking water. Despite
the large amount of evidence in adults of a positive association between serum PFAS and metabolic
outcomes, studies focusing on children and adolescents are limited. We evaluated the associations
between serum PFAS concentrations that were quantifiable in at least 40% of samples and lipid
profile, blood pressure (BP) and body mass index (BMI) in highly exposed adolescents and children.
Methods: A cross-sectional analysis was conducted in 6669 adolescents (14–19 years) and 2693 children
(8–11 years) enrolled in the health surveillance program of the Veneto Region. Non-fasting blood
samples were obtained and analyzed for perfluorooctanoic acid (PFOA), perfluorooctane sulfonate
(PFOS), perfluorohexanesulfonic acid (PFHxS), perfluorononanoic acid (PFNA), total cholesterol (TC),
high-density lipoprotein cholesterol (HDL-C) and triglycerides. Low-density lipoprotein cholesterol
(LDL-C) was calculated. Systolic and diastolic BP were measured, and BMI z-score accounting for age
and sex was estimated. The associations between ln-transformed PFAS (and categorized into quartiles)
and continuous outcomes were assessed using generalized additive models. The weighted quantile
sum regression approach was used to assess PFAS-mixture effects for each outcome. Analyses were
stratified by gender and adjusted for potential confounders. Results: Among adolescents, significant
associations were detected between all investigated PFAS and TC, LDL-C, and to a lesser extent
HDL-C. Among children, PFOS and PFNA had significant associations with TC, LDL-C and HDL-C,
while PFOA and PFHxS had significant associations with HDL-C only. Higher serum concentrations
of PFAS, particularly PFOS, were associated with lower BMI z-score. No statistically significant
associations were observed between PFAS concentrations and BP. These results were confirmed by the
multi-pollutant analysis. Conclusions: Our study supports a consistent association between PFAS
concentration and serum lipids, stronger for PFOS and PFNA and with a greater magnitude among
children compared to adolescents, and a negative association of PFAS with BMI.
Keywords: perfluoroalkyl substances (PFAS); children; adolescents; lipid profile; cholesterol; gener-
alized additive model (GAM); weighted quantile sum (WQS) regression; mixture
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1. Introduction
Over the past few decades, per- and polyfluoroalkyl substance (PFAS) contamination
has grown into a serious global health threat. PFAS are used in numerous consumer
products and industrial applications to confer waterproof, greaseproof, stain-proof and
low-friction properties [1]. PFAS are among the most ubiquitous synthetic chemicals in
the world, and environmental and human exposure to PFAS can occur throughout the life
cycles of these chemicals and products containing them [2]. Humans are exposed to PFAS
via ingestion of contaminated food and drinking water [3], inhalation of indoor air and
indoor dust [4] and use of consumer products. In humans, PFAS half-lives in serum may
vary greatly with expected variation in children (small blood volumes and large fraction
of exposures coming from drinking) compared to adults [5]. Among the numerous PFAS
congeners, only a few PFAS have been thoroughly studied from an epidemiological per-
spective, especially perfluorooctanoic acid (PFOA) and perfluorooctane sulfonate (PFOS).
Adverse impacts have been consistently reported for PFOA and PFOS on the endocrine,
immune, and metabolic outcomes (lipid profile, blood pressure, obesity and metabolic
syndrome) in occupationally exposed, highly exposed, and general populations [6]. De-
spite the large amount of evidence in adults, studies focusing on the association between
serum PFAS and metabolic outcomes in children and adolescents are limited, and the
potential associations for some outcomes have been scarcely studied in European child and
adolescent populations [7–9].
Given the emerging consensus that the development of cardiovascular disease in
adulthood is preceded by metabolic changes occurring in childhood, and considering
interspecies and interindividual differences in concentration–response assessment and
different exposure conditions, it is important to identify the risk associated with exposure
to PFAS in this population. Because both childhood and adolescence are distinguished by
marked changes in growth, sexual maturity and hormonal secretion, the risk of endocrine
disruption by extrinsic agents may differ during these life phases [10]. Furthermore,
the number of underlying factors (e.g., prevalent chronic or acute disease or medication
use) confounding the associations between environmental exposure and potential health
consequences in children and adolescents is likely to be smaller in this population and is
worthy of further insight.
Between the late 1960s and 2013, residents of 30 municipalities across the provinces
of Vicenza, Padova and Verona in the Veneto Region (north-eastern Italy), labelled as Red
Area, were exposed to high concentrations of PFAS, particularly PFOA, via contaminated
drinking water from a manufacturing plant [3]. In this context, the objective of this
study was to evaluate the associations between serum PFAS concentrations and various
cardiometabolic traits (lipid profile, blood pressure, and body mass index) in a large group
of highly exposed adolescents aged 14–19 years and children aged 8–11 years recruited as
part of a community-based health surveillance program in Veneto Region, Italy [3].
2. Materials and Methods
2.1. Study Design and Recruitment
The health surveillance program in Veneto Region is an ongoing cross-sectional study
that started in 2017; it is used to document exposure to PFAS and to evaluate associated
adverse health outcomes in a highly exposed group of community residents of the Reda
Area. The project has been more completely described elsewhere [3]. The participants in
this study were 9475 adolescents aged 14 to 19 years and children aged 8 to 11 years at their
enrollment in the health surveillance program, which happened between January 2017
and December 2019. It represents one of the largest community-based studies to date
investigating potential associations between PFAS exposure and human health effects in
these age groups. Potential participants were sent an invitation letter that explained the
health surveillance program and fixed an appointment. Participants <19 years old had
to be accompanied by a parent or legal guardian. To facilitate recruitment at different
times of the day while minimizing the research impact on school attendance, participants
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were not required to be in fasting conditions. Informed consent from the participants
or their parents/legal guardians was obtained orally and recorded in the individual’s
clinical charts.
2.2. Data Collection
At four different centers (Lonigo, Legnago, San Bonifacio, and Noventa Vicentina),
trained nurses collected personal and medical data, anthropometric measures (height,
weight), blood pressure and blood samples from the participants. Analyses of clinical
biomarkers, including serum lipids, were carried out from three different laboratories
(Arzignano, San Bonifacio, Legnago). Medical history, medications, self-reported height
and weight, socio-demographic information, and lifestyle habits were collected using
interviewer-administered questionnaires.
2.3. Outcomes of Interest
2.3.1. Lipid Profile
Several plasma lipid parameters, including total cholesterol (TC), high-density lipopro-
tein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C), were measured
by a direct enzymatic colorimetric assay using cholesterol esterase and cholesterol oxi-
dase. Triglycerides were measured using an assay based on glycerolphosphate oxidase-
peroxidase aminophenazone. The measurement of serum lipids was performed in a Cobas
automated clinical chemistry analyzer (Roche Diagnostics GmbH, Mannheim, Germany)
in two laboratories and in an AU automated clinical chemistry analyzer (Beckman-Coulter,
Brea, CA, USA) in the third laboratory. The three laboratories regularly follow an exter-
nal quality assurance program. LDL-C was calculated by the Friedewald equation when
triglycerides were less than 400 mg/dL (for 16 subjects it was not possible to calculate it).
2.3.2. Overweight and Obesity
BMI was recalculated after checking the accuracy of data regarding the self-reported
height and weight. Since the relationship between weight and height changes considerably
during the childhood, we converted BMI to a BMI z-score accounting for age and sex using
the recommended WHO Growth References for school-aged children and adolescents [11].
The Z-score system expresses the anthropometric value as a number of standard deviations
or Z-scores below or above the reference mean or median value [12]. A BMI z-score of
≥2 indicates obesity.
This measure was obtained using the R package z-scorer, calculated as a number of
standard deviations above or below the reference median value, based on the WHO Growth
References for school-aged children and adolescents (https://www.who.int/nutgrowthdb/
about/introduction/en/index4.html, accessd on 15 November 2021).
2.3.3. Blood Pressure
Blood pressure (BP) was measured by trained nurses with participants first sitting at
rest for at least five minutes, according to the European Society of Hypertension recom-
mendations. A validated semi-automatic sphygmomanometer with an appropriate cuff
size for the arm circumference was used. If the first measure was above normal values for
age, gender and height, a second measurement was taken at least two minutes apart.
2.4. Serum PFAS Measurement
Serum concentrations of twelve PFAS, consisting of PFOS, PFOA, perfluorohexane-
sulfonic acid (PFHxS), perfluorononanoic acid (PFNA), perfluoroheptanoic acid (PFHpA),
perfluorobutanesulfonic acid (PFBS), perfluorohexanoic acid (PFHxA), perfluorobutanoic
acid (PFBA), perfluoropentanoic acid (PFPeA), perfluorodecanoic acid (PFDeA), perflu-
oroundecanoic acid (PFUnA), and perfluorododecanoic acid (PFDoA), were measured
by high-performance liquid chromatography coupled with triple quadrupole mass spec-
trometry (HPLC MS/MS, Shimadzu UFLC XR 20 Prominence coupled to Sciex API 4000).
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Details of the analytical procedure for measuring the twelve PFAS in serum samples have
been described previously [3]. Method performances allow analytes to be detected as low
as 0.1 ng/mL (LOD) and to be quantified above 0.5 ng/mL (LOQ). Following published
practices, levels less than the LOQ were imputed to be LOQ/
√
2, and we limited our
statistical analyses to PFAS detected in ≥40% of the overall samples. Three of the twelve
PFAS were detected in more than 98% of the serum specimen: PFOA (detected in 99.9% of
adolescents and children), PFOS (detected in 99.8% of adolescents and 99.3% of children),
and PFHxS (detected in 97.6% of adolescents and 96.6% of children). PFNA was detected
in 43.8% of adolescents and 28.3% of children. Detection rates of all PFAS are presented as
supplementary material, Table S1.
2.5. Covariates
Potential confounders were selected through the construction of a directed acyclic
graph (DAG) based on existing literature, and the identification of a minimally sufficient set
of variables to control confounding. The minimally sufficient adjustment set was identified
using DAGitty v1.0 (www.dagitty.net, accessed on 15 November 2021) implemented in R
(R Development Core Team 2010, R Foundation for Statistical Computing, Vienna, Austria.
ISBN 3-900051-07-0, URL: http://www.R-project.org/, accessed on 15 November 2021).
The DAG is presented in supplementary material, Figure S1.
The final model for adjustment included age, gender, country of birth, data on
food consumption, degree of physical activity, salt intake, smoking status (for adoles-
cents only), time-lag between the beginning of the study and the date of enrollment.
Frequency of food consumption was collected for the following food categories: meat,
fish/seafood, milk/yogurt, cheese, eggs, bread/pasta/cereals, sweets/snacks/sweet bev-
erages, fruits/vegetables, and salt. Data on food consumption were transformed from
number of servings per day/week/month to number of servings per week for all the food
categories to create harmonized diet pattern classification. Smoking status was subdivided
into current smokers, previous smokers and non-smokers. Degree of physical activity
(Light, Moderate, or Heavy) was defined based on an algorithm that combined informa-
tion reported by the subject on intensity, duration, and frequency of all types of physical
activity practiced during the week. Countries of birth were classified in two categories
based on geographical areas, including: Italy plus other Highly Developed Countries, and
High Migratory Pressure Countries. The time-lag between the beginning of the study
(1 January 2017) and the date of enrollment was calculated for each subject and included
as a possible covariate (number of months).
Information on the center in charge of the blood pressure and anthropometric mea-
surements was considered as a possible confounder in statistical analyses on blood pressure
and BMI. Lipid models, instead, were adjusted by a laboratory in charge of the analyses
of clinical biomarkers. Analyses on lipids and blood pressure were also adjusted for the
BMI values.
2.6. Statistical Analysis
After excluding pregnant teenagers and subjects with incomplete exposure or outcome
data (supplementary material, Figure S2), 6669 adolescents and 2693 children were included
in the statistical analyses. The serum concentrations of PFAS were expressed as arithmetic
mean, standard deviation (SD) and percentiles. Spearman’s correlation (ρ) was used to
describe pair-wise relations between the PFAS.
All continuous outcomes (Total Cholesterol, HDL Cholesterol, LDL Cholesterol, Sys-
tolic and Diastolic Blood Pressure), except BMI z-score, were analyzed considering a
different subset of observations, excluding those with specific self-reported diseases and
medications. Models for lipid outcomes were fitted excluding subjects under statin drugs
or other cholesterol-lowering medications, and models for blood pressure outcomes were
fitted excluding subjects under anti-hypertensive drugs or with self-reported hypertension.
PFOA, PFOS, PFHxS and PFNA were treated as both continuous, to determine the associa-
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tion between the outcome and the PFAS concentration by linear regression analysis, and
categorical-quartiles of exposure, with the lowest PFAS quartile as a reference group in
order to examine any dose–response trends and limit the influence of extreme values. For
PFNA, due to the high proportion of the measures below the LOQ, PFNA was classified
in three categories: below the limit of quantification, low and medium. The latter two
were defined using a cut-off based on the median of the distribution of PFNA above the
limit of classification. For analysis as a continuous variable, PFAS values were natural log
(ln)-transformed to correct skewed distribution and improve normality of the data.
The relation between each ln-transformed PFAS and continuous outcomes was ana-
lyzed using Generalized Additive Models (GAMs). Thin plate spline smooth terms were
used for the exposure and continuous covariates, in order to explore non-linear shapes of
possible association between PFAS and outcomes. Degree of smoothing was selected by
generalized cross-validation, as implemented in the R package mgcv. The interpretation of
spline analyses does not produce interpretable coefficients besides of EDF, which represents
the degree that a polynomial function (of a specific variable) should have to fit the data
instead of using splines. This implies that a graphical interpretation of predicted values is
the only option. Therefore, since most of the relationships were not incompatible with a
linear fit on the ln-transformed PFAS, linear regression coefficient (β) and 95% Confidence
Intervals (CIs) were reported.
GAM analyses have also been stratified according to gender, and an interaction term
between gender and ln-PFAS was also added to the main models.
Associations between the mixture of the three most represented PFAS (PFOA, PFOS,
and PFHxS) and each outcome were evaluated applying a Weighted Quantile Sum (WQS)
regression model [13]. This approach summarizes the overall exposure creating a weighted
linear index of correlated predictors in terms of quantiles (quartiles in this work), weighted
for the strength of their association with the response. An important toxic PFAS in the
mixture was identified when its weight was≥1/p = 1/3 = 0.33, meaning that it exceeded the
case of uniform weights. Coefficients and their relative 95% CIs were estimated employing
the “gWQS” R package (60% of data were used as an estimation set; 100 Bootstrap samples
were computed). All analyses were fully adjusted for the established set of covariates.
A p-value of <0.05 was considered statistically significant. The statistical software
STATA/SE version 13.0 (Stata Corp LP, College Station, TX, USA) and R (R Development
Core Team 2010, R Foundation for Statistical Computing, Vienna, Austria. ISBN 3-900051-
07-0, URL: http://www.R-project.org/, accessed on 15 November 2021) were used for
statistical analyses.
3. Results
3.1. General Characteristics of the Study Population and PFAS Internal Dose
The general characteristics of children and adolescents who participated in the study
are reported in Tables 1 and 2. The mean age was 16.2 years for adolescents and 9.4 years for
children. The study population included 3411 (51%) males and 3258 (49%) females among
adolescents and 1356 (50%) males and 1337 (50%) females among children. Most partici-
pants were living in the red area from birth (n= 6539, 98% of adolescents, and n = 2669, 99%
of children), therefore being exposed to PFAS via contaminated drinking water from birth.
Percentiles for all PFAS are presented as supplementary material, Table S2. Serum PFOA
levels were an order of magnitude higher than PFOS and PFHxS, with a mean (SD) of 59.7
(53.0) ng/mL in male adolescents and a mean of 43.2 (38.6) ng/mL in female counterparts
(p < 0.001), and 27.6 (22.7) ng/mL and 24.8 (20.2) ng/mL in male and female children,
respectively (p < 0.001). Similar to other studies, PFOA, PFOS and PFHxS concentration
levels were higher in male adolescents compared to females. The gender difference in
serum PFOA, PFOS and PFHxS concentrations was more pronounced in the adolescent age
group. PFAS concentrations were positively correlated with one another with the highest
correlation observed between PFOA and PFHxS with a Spearman correlation coefficient
of 0.93 and 0.89 in adolescents and children, respectively. PFHxS and PFNA were the
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least correlated at 0.34 among adolescents and at 0.20 among children (supplementary
material, Table S3). The distribution and frequencies of the covariates among male and
female adolescents and children are shown in supplementary material, Table S4.
3.2. Generalized Additive Models (GAM)
The regression coefficient for each PFAS (β) and 95% Confidence Intervals (CIs) esti-
mated using generalized additive models (GAMs) are reported in the next three paragraphs,
for lipid serum, blood pressure and BMI z-score, respectively. Full models showing the
effect of all covariates included in the models of the association between PFOS and TC,
SBP and BMI are presented in Tables S5–S7.
3.2.1. Serum Lipids
Among adolescents, differences were observed in the lipid profiles between males
and females, with the latter showing higher levels of TC, HDL-C, and LDL-C, and lower
levels of triglycerides (Table 1). Among children, gender differences on lipid profile were
limited to HDL-C (higher in males) and triglycerides (higher in females) (Table 2).
Table 3 displays the association between single PFAS and serum lipids. Among
adolescents, significant associations were detected between all investigated PFAS and TC,
LDL-C, and to a lesser extent HDL-C in the multivariable model adjusting for various
confounders, and the associations remained significant after categorizing PFAS. Among
children, PFOS and PFNA had significant associations with TC, LDL-C and HDL-C, while
PFOA and PFHxS had significant associations with HDL-C only. The magnitude of the
associations, measured by the increase in each lipid biomarker for a ln-increase in the serum
concentration of PFAS, varied according to the PFAS congener and the age group. With
regard to TC, LDL-C, and HDL-C, the largest effects were observed for PFOS; moreover,
these effects were larger in children compared to adolescents (Table 3).
In adolescents, PFAS/lipids associations were not modified by gender except for
HDL-C with effect significantly higher in girls (supplementary material, Table S8). In
children, the effect of PFOS and PFHxS on TC and LDL-C was significantly higher in girls
than in boys (supplementary material, Table S9).
3.2.2. Blood Pressure
No statistically significant associations were observed between any of the investigated
four PFAS concentrations and blood pressure (Table 4), neither in adolescents nor in
children, after adjustment for covariates when these cardiometabolic traits were modeled
as continuous outcomes in the regression models. The results stratified by gender are
shown in supplementary Tables S10 (adolescents) and S11 (children).
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Table 1. Characteristics of the ADOLESCENTS included in the study population (n = 6669), stratified by gender.
PFAS/Outcomes
Total Males (n = 3411) Females (n = 3258)
Mean (SD) Min–Max Median (Q1–Q3) Mean (SD) Min–Max Median (Q1–Q3) Mean (SD) Min–Max Median (Q1–Q3)
PFAS
PFOA 51.6 (47.2) 0.4–599.3 38.9 (20.1–68.8) 59.7 (53.0) 0.4–599.3 45.2 (24.6–79.3) 43.2 (38.6) 0.4–477.3 33.3 (16.5–58.7)
PFOS 4.1 (3.5) 0.4–86.8 3.3 (2.2–4.9) 4.5 (3.6) 0.4–69.1 3.6 (2.5–5.3) 3.7 (3.2) 0.4–86.8 3.0 (2.0–4.4)
PFHxS 3.6 (2.9) 0.4–27.2 2.8 (1.6–4.8) 4.2 (3.2) 0.4–27.2 3.4 (2.0–5.6) 3.0 (2.3) 0.4–21.6 2.4 (1.3–3.9)
PFNA 0.5 (0.3) 0.4–3.7 0.35 (0.35–0.6) 0.5 (0.2) 0.4–3.7 0.4 (0.4–0.6) 0.5 (0.3) 0.4–3.2 0.4 (0.4–0.6)
OUTCOMES 1
TOTAL CHOLESTEROL 150.5 (27.1) 60–294 148 (132–166) 145.0 (26) 77–290 143 (127–161) 156.2 (27.1) 60–294 153 (138–172)
HDL CHOLESTEROL 54.2 (11.9) 19–124 53 (46–61) 50.1 (10.2) 19–99 49 (43–56) 58.4 (12.0) 24–124 57 (50–66)
LDL CHOLESTEROL 79.5 (23.0) 0–243 77 (64–93) 76.7 (23.0) 0–243 75 (61–90) 82.4 (22.7) 6–211 80 (67–95)
TRYGLICERIDES 84.9 (50.3) 17–699 71 (54–100) 92.3 (58.2) 17–699 76 (56–110) 77.0 (38.8) 17–505 67 (52–90)
BMI z-score 0.3 (1.2) −4.7–4.5 0.26 (−0.5–1.0) 0.3 (1.1) −4.73–4.26 0.28 (-0.38–1.03) 0.25 (1.2) −3.73–4.54 0.2 (-0.6–1.1)
SYSTOLIC BP 114.5 (13.9) 70–190 115 (105–120) 117.9 (14.1) 70–190 120 (110–129) 111.0 (12.8) 70–180 110 (100–120)
DIASTOLIC BP 66.9 (9.6) 30–124.5 70 (60–71) 67.5 (10.0) 30–105 70 (60–75) 66.2 (9.1) 40–124.5 65 (60–70)
1 Reference ranges for lipids: TC < 190 mg/dL, LDL-C < 115 mg/dL, HDL-C > 40 mg/dL, TG < 150 mg/dL.
Table 2. Characteristics of the CHILDREN included in the study population (n = 2693), stratified by gender.
PFAS/Outcomes
Total Males (n = 1356) Females (n = 1337)
Mean (SD) Min–Max Median (Q1–Q3) Mean (SD) Min–Max Median (Q1–Q3) Mean (SD) Min–Max Median (Q1–Q3)
PFAS
PFOA 26.2 (21.5) 0.4–316.3 20.9 (12.9–33.5) 27.6 (22.7) 0.4–316.3 22.5 (13.5–35.82) 24.8 (20.2) 0.4–209.3 19.8 (12.2–31.0)
PFOS 2.6 (2.5) 0.4–96 2.2 (1.6–3.0) 2.6 (3.0) 0.4–96.0 2.2 (1.6–3.1) 2.5 (1.9) 0.4–39.0 2.1 (1.5–2.9)
PFHxS 2.2 (1.5) 0.4–14.6 1.9 (1.2–2.8) 2.3 (1.6) 0.4–14.6 2.0 (1.3–3.0) 2.1 (1.4) 0.4–13.8 1.8 (1.1–2.6)
PFNA 0.4 (0.2) 0.4–3.1 0.4 (0.4–0.5) 0.4 (0.1) 0.4–1.2 0.4 (0.4–0.5) 0.4 (0.2) 04–3.1 0.4 (0.4–0.5)
OUTCOMES 1
TOTAL CHOLESTEROL 160.8 (27.6) 77–389 159 (143–176.0) 161.0 (28.0) 80–357 159 (142–176.0) 160.6 (27.1) 77–389 158 (143–176.0)
HDL CHOLESTEROL 59.5 (12.1) 21–111 59 (51–67.0) 60.7 (12.5) 24–107 60 (52–69.0) 58.3 (11.6) 21–111 58 (50–66.0)
LDL CHOLESTEROL 88.5 (24.8) 16–323 86 (72–102.0) 88.2 (25.1) 19–271 86 (71–102.0) 88.9 (24.5) 16–323 87 (73–102.5)
TRYGLICERIDES 64.0 (31.8) 16–383 57 (43–75.0) 60.9 (31.1) 16–303 54 (40–71.5) 67.1 (32.3) 22–383 60 (46–78.0)
BMI z-score 0.7 (1.3) −5.7–5.6 0.7 (−0.2–1.7) 0.7 (1.2) −3.87–5.61 0.7 (−0.2–1.6) 0.7 (1.4) −5.68–4.71 0.7 (−0.2–1.7)
SYSTOLIC BP 100.0 (11.1) 70–160 100 (90–108) 99.7 (11.1) 70–160 100 (90–108) 100.2 (11.1) 70–142 100 (90–109)
DIASTOLIC BP 62.0 (8.3) 45–100 60 (57–70) 62 (8.3) 45–100 60 (56–70) 62.0 (8.2) 45–93 60 (57–70)
1 Reference ranges for lipids: TC < 190 mg/dL, LDL-C < 115 mg/dL, HDL-C > 40 mg/dL, TG < 150 mg/dL.
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Table 3. Association between ln-PFAS (ln ng/mL) and serum lipids (mg/dL) from GAM models: adjusted β* coefficients and 95% Confidence Intervals (CIs).
PFAS
Adolescents Children
TC HDL LDL TRIGLYCERIDES TC HDL LDL TRIGLYCERIDES
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI)
ln_pfoa 1.05 (0.31, 1.80) −0.17 (−0.47, 0.14) 1.03 (0.39, 1.66) 0.01 (0.00, 0.03) 0.85 (−0.44, 2.14) 0.64 (0.09, 1.19) 0.17 (−0.98, 1.32) 0 (−0.02, 0.02)
II Q 1.18 (−0.60, 2.96) −0.02 (−0.74, 0.71) 1.19 (−0.33, 2.71) 0.01 (−0.02, 0.04) 0.45 (−2.43, 3.33) 0.71 (−0.51, 1.94) −0.23 (−2.8, 2.34) −0.01 (−0.05, 0.04)
III Q 1.68 (−0.18, 3.55) 0.10 (−0.67, 0.86) 1.55 (−0.05, 3.15) 0.00 (−0.03, 0.04) 0.31 (−2.59, 3.21) 1.35 (0.12, 2.58) −1.09 (−3.68, 1.5) −0.01 (−0.05, 0.03)
IV Q 3.20 (1.20, 5.20) −0.30 (−1.12, 0.52) 2.99 (1.27, 4.70) 0.04 (0.01, 0.07) 2.97 (0.02, 5.93) 1.46 (0.20, 2.71) 1.58 (−1.06, 4.21) −0.01 (−0.06, 0.03)
ln_pfos 3.32 (2.20, 4.45) 1.17 (0.71, 1.63) 2.66 (1.70, 3.62) −0.02 (−0.04, 0.00) 6.22 (4.32, 8.13) 1.91 (1.1, 2.73) 4.52 (2.8, 6.23) −0.01 (−0.04, 0.02)
II Q 3.75 (1.98, 5.52) 1.02 (0.29, 1.74) 3.03 (1.51, 4.54) −0.01 (−0.04, 0.02) 3.80 (1.05, 6.56) 2.32 (1.14, 3.49) 2.08 (−0.39, 4.55) −0.02 (−0.07, 0.02)
III Q 4.10 (2.26, 5.95) 1.30 (0.54, 2.05) 3.11 (1.53, 4.69) −0.02 (−0.05, 0.01) 5.82 (2.96, 8.68) 2.35 (1.13, 3.57) 3.52 (0.96, 6.09) 0.01 (−0.04, 0.05)
IV Q 5.84 (3.88, 7.79) 1.83 (1.04, 2.63) 4.63 (2.96, 6.31) −0.03 (−0.06, 0.01) 8.34 (5.51, 11.17) 2.99 (1.78, 4.20) 5.83 (3.28, 8.39) −0.04 (−0.08, 0)
ln_pfhxs 1.49 (0.60, 2.37) −0.05 (−0.41, 0.31) 1.44 (0.68, 2.19) 0.01 (−0.01, 0.02) 1.30 (−0.28, 2.88) 0.8 (0.12, 1.47) 0.54 (−0.87, 1.96) −0.01 (−0.03, 0.01)
II Q 1.96 (0.20, 3.73) −0.16 (−0.88, 0.56) 2.03 (0.52, 3.55) 0.01 (−0.02, 0.04) −1.04 (−3.84, 1.76) 0.46 (−0.73, 1.65) −1.70 (−4.19, 0.8) 0 (−0.04, 0.04)
III Q 1.72 (-0.10, 3.54) 0.14 (−0.60, 0.88) 1.60 (0.05, 3.16) 0.00 (−0.03, 0.03) 0.56 (−2.35, 3.46) 1.68 (0.44, 2.91) −1.22 (−3.81, 1.38) 0 (−0.04, 0.04)
IV Q 3.80 (1.83, 5.77) 0.07 (−0.74, 0.87) 3.65 (1.97, 5.33) 0.02 (−0.02, 0.05) 1.95 (−0.99, 4.89) 1.32 (0.07, 2.56) 0.76 (−1.86, 3.39) −0.02 (−0.07, 0.02)
PFNA low 3.43 (1.91, 4.95) 1.07 (0.45, 1.69) 2.35 (1.05, 3.65) 0.00 (−0.02, 0.03) 2.95 (0.39, 5.50) 1.31 (0.22, 2.40) 1.58 (−0.71, 3.87) −0.01 (−0.05, 0.03)
PFNA medium 3.58 (1.83, 5.33) 1.45 (0.73, 2.17) 3.04 (1.54, 4.54) −0.03 (−0.06, 0.00) 7.53 (3.81, 11.25) 1.8 (0.21, 3.38) 6.06 (2.73, 9.39) −0.02 (−0.07, 0.04)
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Table 4. Association between PFAS (ln ng/mL) and blood pressure (mmHg) from GAM models: adjusted β* coefficients
and 95% Confidence Intervals (CIs).
PFAS
Adolescents Children
SYSTOLIC BP DIASTOLIC BP SYSTOLIC BP DIASTOLIC BP
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI)
ln_pfoa −0.16 (−0.53, 0.20) −0.11 (−0.37, 0.15) −0.51 (−1.02, −0.01) 0.16 (−0.23, 0.54)
II Q −0.44 (−1.31, 0.43) −0.23 (−0.84, 0.39) −0.08 (−1.20, 1.05) 0.58 (−0.28, 1.44)
III Q −1.01 (−1.92, −0.10) −0.28 (−0.93, 0.36) −0.22 (−1.35, 0.91) 0.37 (−0.5, 1.24)
IV Q −0.44 (−1.42, 0.54) −0.08 (−0.77, 0.61) −0.98 (−2.14, 0.18) 0.68 (−0.21, 1.57)
ln_pfos −0.47 (−1.02, 0.08) −0.44 (−0.82, −0.05) −0.42 (−1.18, 0.33) 0.03 (−0.54, 0.61)
II Q −0.67 (−1.54, 0.2) −0.54 (−1.15, 0.08) −0.13 (−1.22, 0.95) 0.67 (−0.16, 1.5)
III Q −0.96 (−1.87, −0.06) −0.66 (−1.30, −0.02) 0.18 (−0.95, 1.31) 0.91 (0.05, 1.77)
IV Q −1.34 (−2.3, −0.38) −0.78 (−1.45, −0.10) −0.8 (−1.92, 0.33) −0.1 (−0.95, 0.75)
ln_PFHxS −0.22 (−0.65, 0.21) −0.15 (−0.45, 0.16) −0.68 (−1.3, −0.06) 0.15 (−0.33, 0.62)
II Q −0.34 (−1.21, 0.52) 0.02 (−0.59, 0.63) −0.53 (−1.62, 0.57) 0.69 (−0.15, 1.54)
III Q −0.71 (−1.6, 0.18) −0.17 (−0.79, 0.46) −1.38 (−2.52, −0.24) 0.19 (−0.68, 1.06)
IV Q −0.37 (−1.33, 0.59) −0.29 (−0.97, 0.39) −1.12 (−2.28, 0.03) 0.3 (−0.58, 1.19)
PFNA low −0.58 (−1.32, 0.17) 0.38 (−0.15, 0.90) −0.45 (−1.45, 0.56) 0.32 (−0.45, 1.08)
PFNA medium −0.33 (−1.19, 0.53) 0.07 (−0.54, 0.68) −0.23 (−1.69, 1.23) −0.91 (−2.03, 0.2)
3.2.3. BMI Z-Score
Higher serum concentrations of PFAS, particularly PFOS, were associated with lower BMI
z-score, among adolescents, with associations more pronounced in females (p-interaction < 0.01
for all PFAS). Greater negative effects were seen among children, with the strongest effect for
PFOS, and with no gender-PFAS significant interactions (Table 5).
3.3. Weighted Quantile Sum (WQS) Models
In the WQS analysis, the weighted quantile sum indices for mixtures showed a positive
association with TC, HDL-C and LDL-C both in adolescents and in children (Table 6). A
one-quartile increase in weighted quantile sum index was associated with a 2.35 mg/dL
(CI: 1.47;3.23) increase in TC in adolescents and a 2.43 mg/dL (CI: 1.24;3.62) increase in
TC in children. Quartile increases in the WQS index were associated with an increase
in the HDL-C concentration of 0.68 mg/dL (CI: 0.34;1.01) and 1.14 mg/dL (0.58;1.70) in
adolescents and children, respectively. Finally, for every quartile increase in the WQS index,
the level of LDL-C increased of 1.79 mg/dL (CI: 0.99;2.59) in adolescents and 1.49 mg/dL
(CI: 0.41;2.58) in children. A decrease in BMI z-score in both groups was also associated with
a quartile increase in the PFAS mixture (−0.08 mmHg with CI: −0.12;−0.04 in adolescents
and −0.1 mmHg with CI: −0.17;−0.03 in children). The level of triglycerides increased of
0.01 mg/dL (CI: 0;0.02), only in adolescents. No significant effect was detected between
the mixture of chemicals and TG, SBP and DBP.
The WQS weights are also shown in Table 6. In adolescents, we identified PFOS as
contributing the most to the weighted quantile sum index for TC (weight: 0.83), HDL-C
(weight: 0.99), LDL-C (weight: 0.54) and BMI (weight: 0.78); PFOA and PFHxS had the
lowest weights for both TC, HDL-C and BMI, but PFHxS was identified as a chemical of
concern for LDL-C (weight: 0.38). For TG, the PFAS with higher weight in the mixture was
PFOA (weight: 0.99). In children, PFOS showed the highest weight for all lipid parameters
(weights: 0.96 for TC, 0.82 for HDL-C, 0.94 for LDL-C), while PFOA and PFHxS never
exceeded the 33% threshold investigating cholesterol levels. PFOS followed by PFHxS
were identified as chemicals of concern for BMI, with contributing weights of 0.51 and
0.40, respectively.
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Table 5. Association between PFAS (ln ng/mL) and BMI z-scores from GAM models: adjusted β* coefficients and 95% Confidence Intervals (CIs), stratified by gender.
PFAS
BMI z-Score—Adolescents BMI z-Score—Children
TOTAL MALES FEMALES TOTAL MALES FEMALES
Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI) Coef (95% CI)
ln_pfoa −0.03 (−0.06, 0.01) 0 (−0.04, 0.04) −0.07 (−0.11, −0.02) −0.08 (−0.14, −0.01) −0.07 (−0.15, 0.01) −0.08 (−0.18, 0.02)
II Q −0.10 (−0.18, −0.02) −0.10 (−0.21, 0.01) −0.09 (−0.2, 0.02) 0.03 (−0.11, 0.17) 0.20 (0.01, 0.39) −0.10 (−0.32, 0.11)
III Q −0.10 (−0.18, −0.02) −0.06 (−0.17, 0.05) −0.11 (−0.23, 0) −0.11 (−0.25, 0.03) 0.01 (−0.18, 0.2) −0.20 (−0.41, 0.02)
IV Q −0.06 (−0.14, 0.03) −0.03 (−0.14, 0.09) −0.16 (−0.29, −0.02) −0.17 (−0.32, −0.03) −0.09 (−0.27, 0.1) −0.25 (−0.48, −0.02)
ln_pfos −0.11 (−0.16, −0.06) −0.10 (−0.17, −0.04) −0.16 (−0.23, −0.09) −0.27 (−0.36, −0.17) −0.24 (−0.36, −0.11) −0.31 (−0.45, −0.17)
II Q −0.14 (−0.22, −0.07) −0.13 (−0.24, −0.02) −0.11 (−0.22, 0) −0.15 (−0.28, −0.01) −0.01 (−0.19, 0.17) −0.29 (−0.5, −0.09)
III Q −0.16 (−0.24, −0.08) −0.14 (−0.26, −0.03) −0.20 (−0.32, −0.09) −0.25 (−0.39, −0.11) −0.16 (−0.35, 0.03) −0.33 (−0.55, −0.12)
IV Q −0.19 (−0.27, −0.1) −0.16 (−0.28, −0.05) −0.26 (−0.39, −0.13) −0.35 (−0.49, −0.21) −0.3 (−0.48, −0.12) −0.42 (−0.63, −0.2)
ln_PFHxS 0.03 (−0.01, 0.07) 0.06 (0.01, 0.11) −0.03 (−0.09, 0.03) −0.13 (−0.21, −0.05) −0.11 (−0.21, −0.01) −0.14 (−0.26, −0.03)
II Q −0.08 (−0.15, 0) 0 (−0.12, 0.11) −0.11 (−0.22, 0) 0.06 (−0.08, 0.2) 0.12 (−0.06, 0.31) 0 (−0.2, 0.21)
III Q 0.01 (−0.07, 0.09) 0.09 (−0.02, 0.2) −0.04 (−0.15, 0.08) −0.20 (−0.34, −0.06) −0.11 (−0.3, 0.08) −0.25 (−0.47, −0.04)
IV Q 0.03 (−0.05, 0.12) 0.12 (0, 0.23) −0.11 (−0.25, 0.02) −0.18 (−0.32, −0.03) −0.12 (−0.31, 0.07) −0.23 (−0.46, −0.01)
PFNA low −0.02 (−0.08, 0.05) 0.03 (−0.06, 0.11) −0.1 (−0.2, 0) −0.25 (−0.38, −0.13) −0.28 (−0.44, −0.13) −0.21 (−0.41, −0.01)
PFNA medium −0.04 (−0.11, 0.04) 0 (−0.1, 0.1) −0.11 (−0.23, 0) −0.36 (−0.54, −0.18) −0.37 (−0.62, −0.12) −0.35 (−0.62, −0.08)
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Table 6. Associations between WQS regression index and serum lipids (mg/dL), blood pressure (mmHg) and BMI. WQS
regression model weights of each PFAS component, for each outcome.
ADOLESCENTS

















PFAS Weights for each outcome
PFOA 0.03 0.00 0.08 0.99 0.22 0.57 0.06
PFOS 0.83 0.99 0.54 0.00 0.78 0.00 0.00
PFHxS 0.14 0.01 0.38 0.01 0.00 0.43 0.94
CHILDREN

















PFAS Weigths for each outcome
PFOA 0.03 0.09 0.03 0.52 0.09 0.01 0.61
PFOS 0.96 0.82 0.94 0.40 0.51 0.92 0.32
PFHxS 0.01 0.09 0.03 0.08 0.40 0.06 0.07
*β represents the increase in cholesterol level and blood pressure associated with a quartile increase in the WQS index. In bold weights that
exceed the case of uniform weights (≥(number of chemicals) − 1 = 0.33).
4. Discussion
4.1. Serum Lipids
In this cross-sectional study on 6669 adolescents and 2693 children exposed to high
levels of PFAS through contaminated drinking water, we found a significant, non-linear
association between serum concentrations of four PFAS congeners and common biomarkers
of lipid metabolism. Compared to PFOA and PFHxS, PFOS and PFNA exhibited stronger
associations and their effects showed a greater magnitude among children compared to
adolescents. The concentration–response curves were sometimes irregular in shape, but in
some instances showed a clear log-linear shape with steeper slopes at lower concentrations.
These findings are quite similar to those we previously reported in a group of more
than 16,000 young adults (age 20–39 years) recruited in the Veneto Region’s health surveil-
lance program [14]; moreover, in that sub-population, we found that PFOS had a stronger
effect compared to PFOA and PFHxS and that the relationship was log-linear.
The effect size was small; however, it should be considered in light of the large
population potentially exposed to low levels of PFAS and of the evidence linking childhood
dyslipidemia to accelerated atherosclerosis, which prompted some scientific associations to
release specific guidelines for cardiovascular risk reduction in children and adolescents [15].
A number of studies examined the association between serum PFAS and serum lipids in
humans [16] but only twelve involved children or adolescents [7–9,17–25]. Even though
the number of studies is relatively small, the evidence quite consistently shows a positive
association between serum PFAS (mainly PFOA and PFOS) and serum cholesterol in
children and adolescents, and the present study further contributes to strengthen that
evidence. In those young age groups, it may be easier to observe adverse effects of
environmental contaminants on the lipid metabolism since the impact of lifestyle habits
has been more limited compared to adults. Most of the abovementioned studies found
significant associations between one or more PFAS congeners and lipid biomarkers in
children or adolescents, with few exceptions [9,22]. The most consistent effects observed
across different studies regarded TC and LDL-C, while fewer studies reported a positive
association with HDL-C [17,21,22,25]. The results varied between studies in terms of the
magnitude and strength of the observed associations and also regarding the involved
congeners. Such heterogeneity may be at least in part attributed to the limited sample
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size of most studies (a few hundred individuals in most instances) and also to differences
in the population ages and exposure levels. All these differences render the available
studies difficult to compare with each other. The study by Frisbee and colleagues [17]
resembles more closely the present one, as it was based on more than 12,000 individuals
aged 1–17 years from a community highly exposed to PFAS through drinking water in
the Mid-Ohio valley, USA. With a cross-sectional design, the authors showed a significant
log-linear association of both serum PFOA and PFOS with TC and LDL-C and of PFOS
with HDL-C. With regard to TC and LDL-C, the magnitude of the association was greater
for PFOS. Altogether, these results are similar to what we found in the Veneto Region’s
exposed population.
Although the literature consistently shows an association between serum PFAS con-
centrations and serum cholesterol levels, it is not clear whether this association is causal or
not. To date, most epidemiological studies, including ours, have been cross-sectional, thus
limiting any causal inference. Cross-sectional studies are subject to bias, such as reverse
causation or confounding, as has also been suggested for the PFAS–lipids associations. In
particular, a confounding effect due to individual variations in the enterohepatic cycling
of PFOS/PFOA and bile acids has been hypothesized [26], and the European Food Safety
Authority has recently reviewed its former decision to consider the increase in serum
cholesterol as one of the critical effects of PFAS exposure [16,27]. As regards children
and adolescents, only four cohort studies have been conducted so far on the associations
between maternal serum PFAS during pregnancy and offspring serum lipids later in
life [8,9,24,25]. The results were inconsistent, with some studies reporting some positive
associations [8,24,25] and others not [9]. Irrespective of this, even a well-conducted cohort
study may provide limited evidence on the causal link between serum PFAS and cholesterol
if the biomarker of exposure (i.e., serum PFAS) is determined only once and the outcome
is assessed after a long delay, since cholesterol levels may be sensitive to modifications of
exposures and the PFAS effect on cholesterol may be transient and reversible. The latter
hypothesis is suggested by a study from the Mid-Ohio valley community, which showed a
greater decrease in serum cholesterol in association with the decrease in serum PFAS [28].
Further studies based on repeated measures of PFAS and lipids levels in the same individ-
uals may contribute to shed light on the intricated issue of the PFAS–lipids association.
We observed some significant gender differences in the associations between PFAS
and serum lipids, and those gender differences varied according to age range. The effect of
PFOA, PFOS, and PFHxS on HDL-C was higher in female adolescents, while the effect of
PFOS and PFHxS on TC and LDL-C was higher in female children. In our previous study on
the young adult population, we observed that the associations between PFAS and HDL-C
were statistically significant only in females [14]. Among other studies, only a few assessed
gender effect modification, with variable findings: in the Mid-Ohio valley community, larger
effects of PFOA and PFOS on TC and LDL-C were found in boys compared to girls [17],
whereas in the study by Mora et al. [25] mid-childhood serum PFOA, PFOS and PFDeA
were associated with a larger increase in TC and LDL-C among girls. Another study [9]
did not find any significant gender differences. Two studies recruited only females and
provided contradictory findings: in a cross-sectional study of girls aged 6–8 years, Fassler
et al. [22] showed a positive association of PFOA with HDL, while the cohort study by
Maisonet et al. [8] showed a positive association of prenatal PFOA (limited to the lower
tertile of the distribution) with TC and LDL-C in followed-up daughters at the ages of 7 and
15 years.
Overall, the results of the combined effects of the PFAS mixture support findings
under the single-chemical linear regressions: higher concentrations of PFAS are associated
with higher levels of serum lipid parameters, especially TC and LDL-C.
Altogether, our findings and the available literature indicate the existence of a very
complex interplay between PFAS exposure and individual characteristics such as gender
and phase of the life course, possibly related to the variation in the internal doses across
genders [29,30] and ages and to the effect of sex hormones on lipid metabolism [31,32].
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In this regard, mechanistic evidence is accruing on a pro-estrogenic and anti-androgenic
effect of PFAS [33,34]. Further mechanistic studies are needed to understand whether these
hormonal perturbations are linked to alterations of lipid metabolism.
4.2. Blood Pressure
To our knowledge, only one study has, by now, found a positive association between
hypertension and PFAS serum levels in an adolescent population, while they did not
find any association of BP as a continuous variable and PFAS concentration [7]. Other
studies, with both cross-sectional and longitudinal design, did not find any significant
association [9,35]. This evidence is supported by our results, for both adolescents and
children, using both GAM models to investigate the single PFAS exposure and WQS
regression models to assess mixture effect on systolic and diastolic blood pressure.
4.3. BMI
Our results, both single- and multi-pollutants, indicate that higher serum concentra-
tions of PFAS, particularly PFOS, were associated with lower BMI z-score during both
childhood and adolescence, with a significant effect of gender in the latter. In the literature,
the outcome of PFAS on adiposity are inconsistent and often contradictory, with studies re-
porting both positive and negative associations, or no association, as discussed below. Few
cross-sectional studies have examined the relationship between childhood/adolescence
exposure to PFAS and BMI/overweight showing inconsistent findings, although the asso-
ciation between prenatal PFOA and BMI was mostly inverse [36,37] or null [38,39], except
for one study [24]. In particular, analysis of the BMI trajectory in infants up to 12 years
old showed that BMI zenith was lower in magnitude in the highest tertile of PFOA [37].
In children aged 3 to 11 years old, PFHxS was negatively associated with weight-for-age
and BMI z-score, but only in males [40]. Recently, Pinney et al. (2019) investigated the
relationship between serum PFOA in girls aged 6–8 years and longitudinal changes in
adiposity at age 6–18 years. The authors reported an inverse association of PFOA level
with BMI z-score, but declining with age [41], which is not in agreement with our data,
although the time window of our study is tighter and the impact of puberty could have
unmasked this association in the Pinney study. In another cohort study on girls aged 6 to
8 years, increasing serum PFOA concentrations were associated with decreased BMIz and
fat mass percent [22].
These findings may support evidence of continued negative effects on weight by
prenatal PFAS exposures. Few studies have investigated the association between PFAS
and adiposity during puberty, with conflicting results according to sex, timing of exposure,
type of study, lifestyle factors (such as physical activity, diet, sleep, and stress) and levels
of exposure. Koshy et al. found no association with overweight in American adoles-
cents exposed to PFHxS, PFOA, PFOS, PFNA, PFDA [20], whereas a Swedish prospective
birth cohort study showed a positive association of PFOS and PFOA exposure with over-
weight/obesity [42]. A large multicenter prospective cohort study (the European Youth
Heart Study) showed that childhood exposure to PFOS and PFOA predicted adiposity at 15
and 21 years of age [10]. A very recent cross-sectional study [7] found a positive association
between PFHxS and PFHpS serum levels with obesity in Norwegian adolescents; however,
this association was not linear and there was no positive association with other PFAS.
In agreement with the literature, we also reported a greater magnitude for the as-
sociation in girls than boys. Indeed, growing evidence suggests that the association of
early-life exposure to certain environmental toxicants with placental functions and risk of
disease later in life may vary by child sex [43]. One possible mechanism to explain gender
differences in the association of PFAS with childhood or adolescent adiposity could be
related to increased cortisol levels associated with PFAS exposure [44] and/or associated to
placental epigenetic processes with sex-specific effects, as observed for maternal stress [45].
As serum levels of androgens and gonadotropins differ between sexes during mini-puberty
in early childhood [46], it cannot be excluded that the observed associations may be in-
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fluenced by sex differences in hormones. In vitro studies [31,32] demonstrated that PFAS
have estrogenic and antiandrogenic activities, but the in vivo consequences to hormonal
interference by PFAS might also differ to receptor sensitivity differences between the two
sexes, due to the physiological homeostasis of sex steroids [47,48]. In addition, PFAS can
inhibit 11-β hydroxysteroid dehydrogenase 2 with subsequent increases in glucocorticoid
concentrations [49], leading to alterations in placental development and function, and
impairment of fetal growth [47]. However, the inverse association between PFAS and BMI
could be confounded by pubertal status, and particularly menstruation status among girls.
Indeed, young women who already had menarche are expected to have lower PFAS levels
due to menstruation loss and higher age-matched BMI.
Since obesity is a complex disease with multifactorial etiology, differences between
studies and populations may be attributable to different genetic and environmental factors,
study designs, concentrations of PFAS, or the timing and method of adiposity measure-
ments. In particular, the differences between cross-sectional and longitudinal studies
might be explained by reverse causation associated with the expanded distribution vol-
umes in obese compared to lean children [39]. For instance, in the longitudinal study
by Liu et al. (2020), prenatal PFAS concentrations were overall weakly correlated with
postnatal PFAS concentrations [48]. In addition, some of the point estimates for postnatal
PFAS concentration were negative, whereas their prenatal counterparts were positive. In
our study, the use of a single serum measure may not fully reflect past exposure, and this
exposure measure does not allow for assessment of prenatal exposures. However, these
substances have long half-lives in humans, which may be upwards of 20 years [30], so
exposure misclassification is less likely. Moreover, it was suggested that PFAS exposure
during foetal life has a minor impact on childhood anthropometry and weight than PFAS
exposure from the environment where children grow up [49].
The mechanism through which PFAS may interfere with childhood and adolescence
adiposity remains unclear. PFAS were found to activate peroxisome proliferator activated
receptor-alpha (PPARα) or (PPARγ), which are essential for the regulation of insulin
signaling, and glucose and lipid metabolism.
In addition, cortisol and sex hormone receptors, together with thyroid metabolism,
have been shown to represent targets of PFAS [50–52]. Since thyroid hormones play a
crucial role in normal growth and development, altered thyroid function can affect early-life
growth and adiposity during critical periods of development. There is a possibility that the
effect of PFAS on early-life growth can be mediated by thyroid hormone disruption. Finally,
the wide variety of pathways altered by PFAS may also reflect the inconsistencies across
studies among different PFAS molecules, since each compound may have different affinities
and magnitudes of effect depending on the targeted pathway and the relative outcome.
4.4. Strengths and Limitations
The strengths of this study include the large population, the accurate measurement of
internal exposure to PFAS, and information on several anthropometric, lifestyle, and clinical
variables, which allowed for the adjustment of many possible confounders. We were able
to model concentration–response curves of PFOA over a wide range of internal doses,
covering both background and high exposure levels. The assessment of the concentration–
response relation over the entire range of exposure makes our results valuable also for
other populations with only background exposure. Moreover, we systematically evaluated
gender-specific associations. Our study suffers from several limitations, however. The
cross-sectional design precludes evaluation of the temporal relationship between exposure
and outcome and thus results may be affected by reverse causation. Moreover, we cannot
exclude covariate misclassification and residual confounding due to unmeasured risk
factors such as sleep and stress. Another important limitation is that in most subjects we
relied on a single blood pressure measurement, which may have led to a non-differential
misclassification of this outcome due to random error.
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5. Conclusions
Our cross-sectional study in children and adolescents supports a positive association
between serum PFAS concentration and serum lipids, stronger for PFOS and PFNA and
with a greater magnitude among children compared to adolescents, and a negative as-
sociation of PFAS with BMI. Additional studies are needed to verify these findings, and
long-term studies that examine growth trajectories from birth through childhood and
adolescence would help elucidate the associations between prenatal PFAS exposure and
growth. Gender differences may come from the limitations of research design, but there
may also be a sex-specific dynamic to PFAS exposure.
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